ALK and non-small cell lung carcinoma: In a phase III randomized trail named ALINA, recently presented at the ESMO Congress 2023, 253 patients with stage IB-IIIA resected ALK-positive NSCLC were randomized to receive either oral alectinib 600 mg twice daily, or four cycles of platinum-based adjuvant chemotherapy [22].